Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis
Objective: to systematize data on cost-effectiveness evaluation of new multidrug and extensively drug-resistant tuberculosis (MDR/XDR-TB) chemotherapy regimens.Material and methods. An analysis of 19 publications devoted to the economic evaluation of the treatment of active MDR/XDR-TB was carried ou...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2022-10-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/714 |
| _version_ | 1797878904725176320 |
|---|---|
| author | А. V. Kukurika |
| author_facet | А. V. Kukurika |
| author_sort | А. V. Kukurika |
| collection | DOAJ |
| description | Objective: to systematize data on cost-effectiveness evaluation of new multidrug and extensively drug-resistant tuberculosis (MDR/XDR-TB) chemotherapy regimens.Material and methods. An analysis of 19 publications devoted to the economic evaluation of the treatment of active MDR/XDR-TB was carried out. The literature search was performed in the electronic databases PubMed/MEDLINE, Google Scholar, eLibrary for the period from January 2015 to February 2022 inclusively.Results. Economic efficiency was studied in high-, middleand low-income countries. All publications contained calculation of treatment costs, and a third of the studies also estimated additional costs. Bedaquiline, delamanid, and pretomanid regimens were included in treatment alone or compared with a background regimen. The most commonly used economic model was the Markov one. To compare primary outcomes, most studies assessed disabilityand quality-adjusted life years. The overall cost of MDR/XDR-TB treatment varied by country income level. In all cases, bedaquiline-based regimens represented a cost-effective alternative to previous treatment, showed high efficacy in MDR/XDR-TB therapy, and were more cost-effective than delamanid regimens.Conclusion. Cost-effective interventions for active MDR/XDR-TB therapy should include the introduction of new chemotherapy regimens, reduced hospital stays and decentralized treatment, which is especially relevant in countries with high tuberculosis burden. |
| first_indexed | 2024-04-10T02:39:27Z |
| format | Article |
| id | doaj.art-d02e20c226a14a0a838975111ab1d459 |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:39:27Z |
| publishDate | 2022-10-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-d02e20c226a14a0a838975111ab1d4592023-03-13T07:48:18ZrusIRBIS LLCФармакоэкономика2070-49092070-49332022-10-0115335336210.17749/2070-4909/farmakoekonomika.2022.131404Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosisА. V. Kukurika0Makeyevka City Tuberculosis DispensaryObjective: to systematize data on cost-effectiveness evaluation of new multidrug and extensively drug-resistant tuberculosis (MDR/XDR-TB) chemotherapy regimens.Material and methods. An analysis of 19 publications devoted to the economic evaluation of the treatment of active MDR/XDR-TB was carried out. The literature search was performed in the electronic databases PubMed/MEDLINE, Google Scholar, eLibrary for the period from January 2015 to February 2022 inclusively.Results. Economic efficiency was studied in high-, middleand low-income countries. All publications contained calculation of treatment costs, and a third of the studies also estimated additional costs. Bedaquiline, delamanid, and pretomanid regimens were included in treatment alone or compared with a background regimen. The most commonly used economic model was the Markov one. To compare primary outcomes, most studies assessed disabilityand quality-adjusted life years. The overall cost of MDR/XDR-TB treatment varied by country income level. In all cases, bedaquiline-based regimens represented a cost-effective alternative to previous treatment, showed high efficacy in MDR/XDR-TB therapy, and were more cost-effective than delamanid regimens.Conclusion. Cost-effective interventions for active MDR/XDR-TB therapy should include the introduction of new chemotherapy regimens, reduced hospital stays and decentralized treatment, which is especially relevant in countries with high tuberculosis burden.https://www.pharmacoeconomics.ru/jour/article/view/714cost-effectiveness analysiseconomic evaluationtuberculosismultidrug resistanceextensively drug resistancenew anti-tuberculosis drugs |
| spellingShingle | А. V. Kukurika Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis Фармакоэкономика cost-effectiveness analysis economic evaluation tuberculosis multidrug resistance extensively drug resistance new anti-tuberculosis drugs |
| title | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis |
| title_full | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis |
| title_fullStr | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis |
| title_full_unstemmed | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis |
| title_short | Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis |
| title_sort | economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis |
| topic | cost-effectiveness analysis economic evaluation tuberculosis multidrug resistance extensively drug resistance new anti-tuberculosis drugs |
| url | https://www.pharmacoeconomics.ru/jour/article/view/714 |
| work_keys_str_mv | AT avkukurika economicaspectsofusingnewchemotherapyregimensformultidrugandextensivelydrugresistanttuberculosis |